EcoDrugPlus

Raf-1 Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSNGAG00000019548
Gene Symbol: RAF1
3 Cross references
216 Possible Orthologues:

Rho Associated Coiled-Coil Containing Protein Kinase 1

Ensembl ID : ENSNGAG00000013091
Gene Symbol: ROCK1
3 Cross references
215 Possible Orthologues:

Rho Associated Coiled-Coil Containing Protein Kinase 2

Ensembl ID : ENSNGAG00000019681
Gene Symbol: ROCK2
3 Cross references
304 Possible Orthologues:

Sem1 26s Proteasome Complex Subunit

Ensembl ID : ENSNGAG00000004905
Gene Symbol: SEM1
3 Cross references
155 Possible Orthologues:

Src Proto-Oncogene, Non-Receptor Tyrosine Kinase

Ensembl ID : ENSNGAG00000003604
Gene Symbol: SRC
3 Cross references
262 Possible Orthologues:

Tek Receptor Tyrosine Kinase

Ensembl ID : ENSNGAG00000019538
Gene Symbol: TEK
3 Cross references
164 Possible Orthologues:

Ttk Protein Kinase

Ensembl ID : ENSNGAG00000008755
Gene Symbol: TTK
3 Cross references
203 Possible Orthologues:

Udp-Glucose Ceramide Glucosyltransferase

Ensembl ID : ENSNGAG00000021959
Gene Symbol: UGCG
3 Cross references
211 Possible Orthologues:

Wee1 G2 Checkpoint Kinase

Ensembl ID : ENSNGAG00000017048
Gene Symbol: WEE1
3 Cross references
226 Possible Orthologues:

Yes Proto-Oncogene 1, Src Family Tyrosine Kinase

Ensembl ID : ENSNGAG00000024151
Gene Symbol: YES1
3 Cross references
263 Possible Orthologues:

Acetylcholinesterase (Cartwright Blood Group)

Ensembl ID : ENSNGAG00000007886
Gene Symbol: ACHE
3 Cross references
233 Possible Orthologues:

Activin A Receptor Like Type 1

Ensembl ID : ENSNGAG00000010548
Gene Symbol: ACVRL1
3 Cross references
353 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).